S2E11 - Mary Canavan, JD, Kyle A. Vasquez, JD, LLM | Post-Scrip: The ASPL Pharmacy Law Podcast
Listen now
Description
In this episode of Post-Scrip, Henry introduces Mary Canavan, JD and Kyle A. Vasquez, JD, LLM. They discuss the upcoming 340B Program Preservation and Compliance. In this session, participants will learn how use the 340B statute and guidance to preserve 340B savings. In a climate where manufacturers and payors are uniformly taking action that harms covered entities (and patients), covered entities need to be prepared and start adapting. While manufacturer restrictions have been at the forefront of the 340B industry recently, there are several other stakeholders that are also taking actions that harm 340B savings such as PBMs.  As a result of these actions restricting the use of 340B drugs, covered entities have to become creative with how they internally build out their 340B programs, but due to the limited guidance available, the focus on compliance is more important than ever. This session will walk covered entities through case studies that demonstrate how other covered entities are becoming innovators and adjusting their 340B operations to preserve 340B savings. These models assess several areas of compliance, including: 340B, reimbursement, scope of practice, and telehealth. Join us at the 34th annual conference:  Developments in Pharmacy Law Seminar , November 2-5, 2023 in San Antonio, Texas
More Episodes
In this episode of Post-Scrip, Henry introduces Jenni Wai, RPh. , MBA, Josh Bolin and Christopher R. Smith, JD, LLM. They discuss the upcoming "Regulatory, Industry and Legal Perspectives on the Future of the DSCSA".This presentation will provide an update on the final stages of implementation of...
Published 10/16/24
In this episode of Post-Scrip, Henry introduces Marty Allain, JD. They discuss the upcoming "How Drug Manufacturer Restrictions and Recent Court Decisions are Re-Shaping 340B Drug Distribution and Delivery Models".Pharmaceutical manufacturers continue to restrict the delivery of 340B drug...
Published 10/09/24